Compare StocksABBV vs BSX

AbbVie Inc. (ABBV) vs Boston Scientific Corporation (BSX): Which Is the Better Buy in 2026?

As of 2026-08-03, ABBV is overvalued at $251, with a DCF intrinsic value of $178 and a margin of safety of -41%. BSX is overvalued at $47, with an intrinsic value of $30 and a margin of safety of -54%. Of the two, ABBV has the wider margin of safety.

ABBV
AbbVie Inc.
$250.94
VS
BSX
Boston Scientific Corporation
$46.73

Rewards

ABBV
  • AbbVie Inc. has maintained ROIC above 10% for 4 consecutive years, suggesting solid business economics.
  • Gross margin of 72.8% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
  • AbbVie Inc. scores 82/100 on the Economic Moat Score (Wide Moat), with reinvestment efficiency as the strongest competitive dimension.
BSX
  • Gross margin of 69.3% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
  • Free cash flow has grown at a 55.0% CAGR over the past 4 years, demonstrating strong earnings power growth.
  • Each dollar of retained earnings has created $3.37 of earning power — management is an exceptional capital allocator.

Risks

ABBV
  • Buybacks have been poorly timed — 3 out of 4 years involved repurchases at relatively expensive valuations.
  • Free cash flow has declined at a 9.8% CAGR over the past 4 years — a concerning trend.
BSX

    Key Valuation Metrics

    Learn more →
    ABBV
    BSX
    Valuation
    N/A
    Free Cash Flow
    N/A
    N/A
    FCF Yield
    N/A
    70.89
    Trailing P/E
    18.92
    15.41
    Forward P/E
    13.57
    Quality & Moat
    27.60%
    ROIC
    10.68%
    N/A
    ROE
    11.10%
    72.79%
    Gross Margin
    69.28%
    0.41
    PEG Ratio
    0.67
    Balance Sheet Safety
    N/A
    Net Debt / Equity
    0.37
    N/A
    Interest Coverage
    N/A
    2.06
    Net Debt / EBITDA
    1.67
    2.76%
    Dividend Yield
    0.00%
    ABBV: 3Ties: 2BSX: 3
    ABBVBSX

    Historical Fundamentals

    Learn more →
    ABBV

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    BSX

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    $1 Retained Earnings Test

    Learn more →
    ABBV
    N/A
    Net losses over 3 years — test not applicable
    Company had negative cumulative retained earnings
    Σ Retained
    $-19.85B
    Δ Market Cap
    +$118.02B
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
    BSX
    $11.89
    created per $1 retained over 3 years
    Exceptional Value Creator
    Σ Retained
    $6.32B
    Δ Market Cap
    +$75.08B
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Discounted Cash Flow (DCF) Analysis

    Learn more →
    ABBV
    40.7% Overvalued
    Price is 40.7% above estimated fair value
    Current Price: $250.94
    Fair Value: $178.31
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued
    BSX
    53.8% Overvalued
    Price is 53.8% above estimated fair value
    Current Price: $46.73
    Fair Value: $30.38
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued

    Reverse DCF — Market-Implied Growth

    Learn more →
    ABBV

    Requires positive FCF to compute implied growth rate.

    BSX

    Requires positive FCF to compute implied growth rate.

    Economic Moat Score

    Learn more →
    ABBV
    82/100
    Wide Moat
    70+ Wide · 40-69 Narrow · <40 None

    Wide moat with strength across all dimensions. Reinvestment Efficiency is the standout factor.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.
    BSX
    66/100
    Narrow Moat
    70+ Wide · 40-69 Narrow · <40 None

    Narrow moat with revenue predictability as the key competitive advantage. Improving roic consistency would strengthen the moat.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 5 years of fundamental data.

    Forensic Accounting

    Learn more →
    ABBV
    -2.86
    Unlikely Manipulator
    Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

    M-Score Trend

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
    BSX
    -2.51
    Unlikely Manipulator
    Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

    M-Score Trend

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

    Ownership Breakdown

    Learn more →
    ABBV
    Insiders 0.1%Institutions 76.9%Retail & Other 23.0%
    No. of Institutional Holders5,146
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
    BSX
    Insiders 0.2%Institutions 93.0%Retail & Other 6.7%
    No. of Institutional Holders2,292
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

    High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

    Insider Buying Activity

    Learn more →
    ABBV
    0
    Buys (3M)
    0
    Buys (12M)
    No open market insider purchases found.
    Open market purchases · includes direct & indirect ownership · excludes option exercises
    BSX
    3
    Buys (3M)
    3
    Buys (12M)
    Total value (12M): $553,999
    LUDWIG EDWARD J.
    Director
    $202,914
    @ $56.68 · 2026-05-20
    HABIGER DAVID C
    Director
    $251,098
    @ $56.43 · 2026-05-20
    PEGUS CHERYL
    Director
    $99,987
    @ $56.49 · 2026-05-20
    FITZGERALD JOSEPH MICHAEL
    Officer
    $4,515
    @ $90.30 · 2024-12-03
    Open market purchases · includes direct & indirect ownership · excludes option exercises

    Open market purchases · includes direct & indirect ownership · excludes option exercises.

    Insider Selling Activity

    Learn more →
    ABBV
    0
    Sells (3M)
    5
    Sells (12M)
    Total value (12M): $21.79M
    PURDUE DAVID RYAN
    Officer
    $1.22M
    @ $233.56 · 2026-03-04
    SIATIS PERRY C.
    General Counsel
    $4.38M
    @ $234.39 · 2026-03-02
    SIATIS PERRY C.
    General Counsel
    $5.15M
    @ $230.00 · 2026-02-25
    SALEKI-GERHARDT AZITA
    Chief Operating Officer
    $8.41M
    @ $198.42 · 2025-08-12
    DONOGHOE NICHOLAS
    Officer
    $2.64M
    @ $198.51 · 2025-08-05
    STEWART JEFFREY RYAN
    Officer
    $12.36M
    @ $210.08 · 2025-03-31
    REENTS SCOTT T.
    Chief Financial Officer
    $3.75M
    @ $212.34 · 2025-03-14
    SIATIS PERRY C.
    General Counsel
    $5.82M
    @ $208.69 · 2025-03-03
    GONZALEZ RICHARD A
    Director
    $20.26M
    @ $205.45 · 2025-03-03
    RICHMOND TIMOTHY J
    Officer
    $4.47M
    @ $210.45 · 2025-03-03
    BUCKBEE KEVIN K
    Officer
    $3.85M
    @ $203.41 · 2025-02-26
    RICHMOND TIMOTHY J
    Officer
    $6.07M
    @ $202.90 · 2025-02-26
    SIATIS PERRY C.
    General Counsel
    $1.14M
    @ $197.90 · 2025-02-20
    BUCKBEE KEVIN K
    Officer
    $310,032
    @ $172.24 · 2024-12-16
    GONZALEZ RICHARD A
    Officer and Director
    $12.40M
    @ $186.52 · 2024-08-05
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
    BSX
    0
    Sells (3M)
    7
    Sells (12M)
    Total value (12M): $34.54M
    MAHONEY MICHAEL F
    Chief Executive Officer
    $15.04M
    @ $93.49 · 2026-02-02
    BUTCHER ARTHUR C
    Officer
    $1.76M
    @ $101.55 · 2025-12-01
    ZANE ELLEN M
    Director
    $1.27M
    @ $98.28 · 2025-11-06
    FITZGERALD JOSEPH MICHAEL
    Officer
    $4.97M
    @ $99.47 · 2025-11-03
    ZANE ELLEN M
    Director
    $1.31M
    @ $101.38 · 2025-10-28
    FITZGERALD JOSEPH MICHAEL
    Officer
    $4.92M
    @ $98.47 · 2025-10-01
    FITZGERALD JOSEPH MICHAEL
    Officer
    $5.27M
    @ $105.43 · 2025-09-02
    FITZGERALD JOSEPH MICHAEL
    Officer
    $5.23M
    @ $104.63 · 2025-08-01
    BUTCHER ARTHUR C
    Officer
    $1.81M
    @ $104.63 · 2025-08-01
    FUJIMORI YOSHIAKI
    Director
    $310,378
    @ $106.99 · 2025-07-29
    LUDWIG EDWARD J.
    Director
    $424,120
    @ $106.03 · 2025-07-25
    FITZGERALD JOSEPH MICHAEL
    Officer
    $5.35M
    @ $106.97 · 2025-07-01
    FITZGERALD JOSEPH MICHAEL
    President
    $5.80M
    @ $102.88 · 2025-06-04
    MAHONEY MICHAEL F
    Chief Executive Officer
    $17.05M
    @ $103.69 · 2025-06-02
    LUDWIG EDWARD J.
    Director
    $418,368
    @ $104.59 · 2025-05-29
    BROWN VANCE R
    General Counsel
    $513,583
    @ $106.42 · 2025-05-21
    SORENSON JOHN BRADLEY
    Officer
    $477,957
    @ $104.54 · 2025-05-05
    MAHONEY MICHAEL F
    Chief Executive Officer
    $16.85M
    @ $102.48 · 2025-05-01
    BUTCHER ARTHUR C
    Officer
    $1.77M
    @ $102.06 · 2025-05-01
    BROWN VANCE R
    General Counsel
    $458,904
    @ $95.09 · 2025-04-21
    MAHONEY MICHAEL F
    Chief Executive Officer
    $16.45M
    @ $100.01 · 2025-04-01
    BROWN VANCE R
    General Counsel
    $486,702
    @ $100.85 · 2025-03-21
    WOODWORTH EMILY
    General Counsel
    $800,897
    @ $104.95 · 2025-03-04
    WOODWORTH EMILY
    Officer
    $999,872
    @ $101.13 · 2025-02-28
    MIRVISS JEFFREY B
    Officer
    $766,921
    @ $104.16 · 2025-02-25
    ZANE ELLEN M
    Director
    $1.42M
    @ $104.23 · 2025-02-24
    BROWN VANCE R
    General Counsel
    $504,993
    @ $104.64 · 2025-02-21
    SORENSON JOHN BRADLEY
    Officer
    $624,861
    @ $104.84 · 2025-02-19
    BRENNAN DANIEL J
    Chief Financial Officer
    $8.92M
    @ $105.10 · 2025-02-19
    MIRVISS JEFFREY B
    Officer
    $159,078
    @ $105.35 · 2025-02-19
    SORENSON JOHN BRADLEY
    Officer
    $127,678
    @ $106.31 · 2025-02-14
    SORENSON JOHN BRADLEY
    Officer
    $671,249
    @ $105.06 · 2025-02-12
    BRENNAN DANIEL J
    Chief Financial Officer
    $1.59M
    @ $105.07 · 2025-02-12
    MIRVISS JEFFREY B
    Officer
    $1.37M
    @ $105.06 · 2025-02-12
    LUDWIG EDWARD J.
    Director
    $1.27M
    @ $105.48 · 2025-02-11
    SORENSON JOHN BRADLEY
    Officer
    $685,244
    @ $104.97 · 2025-02-07
    BUTCHER ARTHUR C
    Officer
    $1.76M
    @ $101.80 · 2025-02-03
    SORENSON JOHN BRADLEY
    Officer
    $581,241
    @ $89.96 · 2025-01-03
    BRENNAN DANIEL J
    Chief Financial Officer
    $870,636
    @ $89.86 · 2025-01-03
    MIRVISS JEFFREY B
    Officer
    $642,658
    @ $89.86 · 2025-01-03
    FITZGERALD JOSEPH MICHAEL
    Officer
    $1,799
    @ $89.95 · 2024-12-10
    CARRUTHERS WENDY
    Officer
    $633,917
    @ $90.78 · 2024-12-02
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

    🎭 Mr. Market's Mood

    Learn more →
    ABBV
    FearGreed
    😏Greed(61/100)

    "Market is optimistic — be cautious and ensure you have a margin of safety"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
    BSX
    FearGreed
    😨Fear(40/100)

    "Market is pessimistic — investigate whether fears are temporary or structural"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    ⚖️ Buffett Signal

    Learn more →
    ABBV
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Greed (61)
    BSX
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Fear (40)
    View ABBV Full AnalysisView BSX Full Analysis

    Frequently Asked Questions: ABBV vs BSX

    Is AbbVie Inc. or Boston Scientific Corporation more undervalued in 2026?

    Based on our discounted cash flow model, ABBV trades at a -40.7% margin of safety (intrinsic value $178 vs. price $251), compared to BSX's -53.8% margin of safety (intrinsic $30 vs. $47).

    Which stock has a wider economic moat, AbbVie Inc. or Boston Scientific Corporation?

    ABBV scores 82/100 (Wide moat), while BSX scores 66/100 (Narrow moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

    Is AbbVie Inc. in financial distress?

    ABBV's Altman Z-Score of 2.4 places it in the Grey zone, signaling elevated bankruptcy risk. BSX scores 5.5 (Safe zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

    Which stock has higher return on invested capital, AbbVie Inc. or Boston Scientific Corporation?

    ABBV earns 27.6% ROIC versus BSX's 10.7%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.